MARKET

CNTB

CNTB

Connect Biopharma Holdings Ltd
NASDAQ
2.380
0.000
0.00%
After Hours: 2.380 0 0.00% 16:51 06/30 EDT
OPEN
2.400
PREV CLOSE
2.380
HIGH
2.480
LOW
2.370
VOLUME
591.81K
TURNOVER
--
52 WEEK HIGH
3.820
52 WEEK LOW
0.9800
MARKET CAP
149.85M
P/E (TTM)
-2.0629
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (CGON), Alnylam Pharma (ALNY) and Connect Biopharma Holdings (CNTB)
TipRanks · 11h ago
Weekly Report: what happened at CNTB last week (0622-0626)?
Weekly Report · 1d ago
Connect Biopharma Price Target Announced at $7.00/Share by Piper Sandler
Dow Jones · 4d ago
Piper Sandler Initiates Coverage On Connect Biopharma Hldgs with Overweight Rating, Announces Price Target of $7
Benzinga · 4d ago
Biren Amin Initiates Buy on Rademikibart Developer with Overweight Rating and DCF-Based $7 Price Target on Differentiated Asthma/COPD Opportunity
TipRanks · 4d ago
Connect Biopharma initiated with an Overweight at Piper Sandler
TipRanks · 4d ago
CONNECT BIOPHARMA HOLDINGS LTD <CNTB.O>: PIPER SANDLER INITIATES COVERAGE WITH OVERWEIGHT RATING; TARGET PRICE $7
Reuters · 4d ago
HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target
Benzinga · 5d ago
More
About CNTB
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.

Webull offers Connect Biopharma Holdings Ltd (ADR) stock information, including NASDAQ: CNTB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNTB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CNTB stock methods without spending real money on the virtual paper trading platform.